Safety
The safety of TIBSOVO was evaluated in patients with advanced mIDH1 CCA reflective of that seen in clinical practice2
Learn moreA recommended treatment option in advanced cholangiocarcinoma
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend ivosidenib (TIBSOVO) as a subsequent line treatment option for unresectable or metastatic cholangiocarcinoma with an IDH1 mutation following disease progression4
View practice recommendations
Convenient, once-daily oral dosing1
View dosingReferences: 1. Popovici-Muller J, Lemieux RM, Artin E, et al. Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300-305. doi:10.1021/acsmedchemlett.7b00421 2. Tibsovo. Package insert. Servier Pharmaceuticals LLC; 2022. 3. Data on file. Servier Pharmaceuticals LLC. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatobiliary Cancers V.5.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed January 17, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.